VistaGen Therapeutics, Inc.
VTGN
$0.70
$0.0913.85%
NASDAQ
| 03/31/2026 | 12/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | 53.47% | 17.44% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 53.47% | 17.44% | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | 53.47% | 17.44% | |||
| SG&A Expenses | -26.73% | 27.98% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -13.44% | -2.27% | |||
| Operating Income | 14.47% | 2.53% | |||
| Income Before Tax | 13.93% | 2.67% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 13.89% | 2.67% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 13.89% | 2.67% | |||
| EBIT | 14.47% | 2.53% | |||
| EBITDA | 14.50% | 2.54% | |||
| EPS Basic | 14.08% | 17.60% | |||
| Normalized Basic EPS | 14.12% | 17.61% | |||
| EPS Diluted | 14.08% | 17.60% | |||
| Normalized Diluted EPS | 14.12% | 17.61% | |||
| Average Basic Shares Outstanding | 0.23% | 18.14% | |||
| Average Diluted Shares Outstanding | 0.23% | 18.14% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||